| 1 |
Humira (adalimumab) |
CHO |
AbbVie |
1 |
Moderate to severe rheumatoid arthritis, moderate to severe chronic plaque psoriasis, moderate to severe Crohn’s disease; moderate to severe ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, moderate to severe polyarticular juvenile idiopathic arthritis |
| 2 |
Opdivo (nivolumab) |
not listed |
Bristol- Myers Squibb and Ono |
3 |
Indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. |
| 3 |
Enbrel (etanercept) |
CHO |
Amgen and Pfizer |
6 |
Moderate to severe plaque psoriasis, psoriatic arthritis, and moderate to severe rheumatoid arthritis |
| 4 |
Remicade (infliximab) |
Murine Myeloma |
Johnson & Johnson and Merck & Co. |
8 |
Moderately to severely active rheumatoid arthritis in adults, in combination with methotrexate; Crohn’s Disease in children 6 years and older, and adults who have not responded well to other medicines; rheumatoid arthritis; ankylosing spondylitis; psoriatic arthritis; chronic, severe, extensive, and/or disabling plaque psoriasis in adults; moderately to severely active ulcerative colitis in children 6 years and older and adults that have not responded well to other medicines |
| 5 |
Avastin (bevacizumab) |
CHO |
Roche |
9 |
Metastatic colorectal cancer (colon cancer), non–small cell lung cancer, glioblastoma & metastatic kidney |
| 6 |
Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine) |
|
Pfizer |
10 |
Prevention of diseases caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in children ages six weeks through 17 years; prevention of otitis media caused by strains 4, 6B, 9V, 14, 18C, 19F, and 23F in children six weeks through five years; prevention of pneumococcal pneumonia and invasive disease caused by the 13 vaccine strains in adults ages 50 and older |
| 7 |
Eylea (aflibercept) |
CHO |
Regeneron |
11 |
Wet Age-related Macular Degeneration, Macular Edema following Retinal Vein Occlusion, Diabetic Macular Edema and Diabetic Retinopathy. |
| 8 |
Soliris (eculizumab) |
Murine Myeloma |
Alexion Pharmaceuticals |
14 |
Atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria. |
| 9 |
Herceptin (trastuzumab) |
CHO |
Roche |
15 |
HER2-positive breast cancer and HER2-positive metastatic gastric cancer |
| 10 |
Rituxan |
CHO |
Roche and Biogen Idec |
17 |
Non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis |
